Drug name - Xarelto

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7157456 JANSSEN PHARMS Substituted oxazolidinones and their use in the field of blood coagulation
Aug, 2024

(1 year, 10 months from now)

CN1900074A JANSSEN PHARMS Substituted Oxazolidinones And Their Use In The Field Of Blood Coagulation
Dec, 2020

(1 year, 9 months ago)

CN1434822A JANSSEN PHARMS Substituted Oxazolidinones And Their Use In The Field Of Blood Coagulation
Dec, 2020

(1 year, 9 months ago)

CN1262551C JANSSEN PHARMS Substituted Oxazolidinones And Their Use In The Field Of Blood Coagulation
Dec, 2020

(1 year, 9 months ago)

CN1900074B JANSSEN PHARMS Substituted Oxazolidinones And Their Use In The Field Of Blood Coagulation
Dec, 2020

(1 year, 9 months ago)

CN1772751A JANSSEN PHARMS Substituted Oxazolidinones And Their Use In The Field Of Blood Coagulation
Dec, 2020

(1 year, 9 months ago)

CN100549008C JANSSEN PHARMS Substituted Oxazole Alkyl Ketone And Application Thereof In The Field Of Blood Coagulation
Dec, 2020

(1 year, 9 months ago)

IN200200763P3 JANSSEN PHARMS Oxazolidinones And Their Use
Dec, 2020

(1 year, 9 months ago)

IN211300B JANSSEN PHARMS Oxazolidinones And Their Use
Dec, 2020

(1 year, 9 months ago)

EP1526132B1 JANSSEN PHARMS Substituted Oxazolidinone Derivatives And Their Use As Factor Xa Inhibitors
Dec, 2020

(1 year, 9 months ago)

EP1526132A3 JANSSEN PHARMS Substituted Oxazolidinone Derivatives And Their Use As Factor Xa Inhibitors
Dec, 2020

(1 year, 9 months ago)

EP1526132A2 JANSSEN PHARMS Substituted Oxazolidinone Derivatives And Their Use As Factor Xa Inhibitors
Dec, 2020

(1 year, 9 months ago)

EP1261606A1 JANSSEN PHARMS Substituted Oxazolidinones And Their Use In The Field Of Blood Coagulation
Sep, 2023

(11 months from now)

EP1261606B1 JANSSEN PHARMS Substituted Oxazolidinones And Their Use In The Field Of Blood Coagulation
Sep, 2023

(11 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9415053 JANSSEN PHARMS Solid, orally administrable pharmaceutical composition Nov, 2024

(2 years from now)

US7157456

(Pediatric)

JANSSEN PHARMS Substituted oxazolidinones and their use in the field of blood coagulation Feb, 2025

(2 years from now)

US9415053

(Pediatric)

JANSSEN PHARMS Solid, orally administrable pharmaceutical composition May, 2025

(2 years from now)

US9539218 JANSSEN PHARMS Prevention and treatment of thromboembolic disorders Feb, 2034

(11 years from now)

US9539218

(Pediatric)

JANSSEN PHARMS Prevention and treatment of thromboembolic disorders Aug, 2034

(11 years from now)

US10828310 JANSSEN PHARMS Reducing the risk of cardiovascular events Jan, 2039

(16 years from now)

US10828310

(Pediatric)

JANSSEN PHARMS Reducing the risk of cardiovascular events Jul, 2039

(16 years from now)

Drugs and Companies using RIVAROXABAN ingredient

Treatment: Reducing the risk of stroke and systemic embolism; treatment of pulmonary embolism (pe); treatment of deep vein thrombosis (dvt); reduction of risk of major cardiovascular events (cv death, mi, and stroke) in chronic cad or pad; prophylaxis of venous thromboembolism in acutely ill medical patients at risk for thromboembolic complications not at high risk of bleeding; prophylaxis of thromboembolic diseases in pediatric patients aged 2 years and older with congenital heart disease who have undergone the fontan procedure and a body weight of >=50 kg; treatment of venous thromboembolism (vte) and the reduction in the risk of recurrent vte in pediatric patients from birth to less than 18 years with a body weight of 30 kg to 49.9 kg after at least 5 days of initial parenteral anticoagulant treatment; reduction in the risk of recurrence of deep vein thrombosis (dvt) and/or pulmonary embolism (pe) in patients at continued risk for recurrent dvt and/or after completion of initial treatment lasting at least 6 months; prophylaxis of deep vein thrombosis (dvt); reduction of risk of major cardiovascular events (cardiovascular death, myocardial infarction and stroke) in patients with cad; reduction of risk of major thrombotic vascular events (myocardial infarction, ischemic stroke, acute limb ischemia, and major amputation of vascular etiology) in patients with pad; treatment of venous thromboembolism (vte) and the reduction in the risk of recurrent vte in pediatric patients from birth to less than 18 years with a body weight of >=50 kg after at least 5 days of initial parenteral anticoagulant treatment; Treatment of pulmonary embolism with once daily, rapid-release tablet administered for at least five consecutive days; treatment of deep vein thrombosis with once daily, rapid-release tablet administered for at least five consecutive days; prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism in patients undergoing knee or hip replacement surgery, with once daily, rapid-release tablet administered for at least five consecutive days; reduce the risk of stroke in patients with nonvalvular atrial fibrillation with once daily, rapid-release tablet administered for at least five consecutive days; prophylaxis of venous thromboembolism in acutely ill medical patients at risk for thromboembolic complications not at high risk of bleeding with once daily, rapid-release tablet administered for at least 5 consecutive days; treatment of dvt and/or pe and reduction in the risk of recurrent dvt and/or pe in pediatric patients (>=50 kg) once daily with rapid-release tablet administered for at least 5 consecutive days after at least 5 days parenteral anticoagulant treatment; after completion of initial treatment lasting at least 6 months, to reduce the risk of recurrence of deep vein thrombosis and/or pulmonary embolism in certain patients with once daily, rapid-release tablet administered for at least 5 consecutive days; prophylaxis of pe, dvt and/or stroke in pediatric patients (>=50 kg) aged 2 years and older with congenital heart disease after fontan procedure with once daily, rapid-release tablet administered for at least 5 consecutive days; treatment of dvt and/or pe and reduction in risk of recurrent dvt and/or pe in pediatric patients (30-49.9 kg) once daily with rapid-release tablet administered for at least 5 consecutive days after at least 5 days parenteral anticoagulant treatment; Reduction of risk of cardiovascular death, myocardial infarction, and stroke in patients with cad by administering clinically proven effective amounts that are 2.5 mg rivaroxaban twice daily and 75-100 mg aspirin daily; reduction of risk of myocardial infarction and ischemic stroke in patients with pad by administering clinically proven effective amounts that are 2.5 mg rivaroxaban twice daily and 75-100 mg aspirin daily

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
2.5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription
15MG TABLET;ORAL Prescription
20MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.